

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001511365
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer AcelRx Pharmaceuticals Inc.
SEC File Number 001-35068
Address of Issuer 180 Gateway Drive #175
San Mateo
CALIFORNIA
94404
Phone 650-216-3500
Name of Person for Whose Account the Securities are To Be Sold Pamela Palmer, Trustee of the Pamela P Palmer Revocable Trust DTD 10/17/2014

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Stock	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	7450	8195	16340000	08/25/2023	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the	Date you	Nature of	Name of Person	Is	Date	Amount of	Date of	Nature of
--------------	----------	-----------	----------------	----	------	-----------	---------	-----------

Class	Acquired	Acquisition Transaction	from Whom Acquired	this Donor a Acquired Gift?	Securities Acquired	Payment	Payment *
Class A	06/09/2011	RSUs/Options Exercise	AcelRx Pharmaceuticals	<input type="checkbox"/>	439	06/09/2011	Electronic
Class A	08/31/2011	RSUs/Options Exercise	AcelRx Pharmaceuticals	<input type="checkbox"/>	250	08/31/2011	Electronic
Class A	09/02/2011	RSUs/Options Exercise	AcelRx Pharmaceuticals	<input type="checkbox"/>	845	09/02/2011	Electronic
Class A	02/29/2012	RSUs/Options Exercise	AcelRx Pharmaceuticals	<input type="checkbox"/>	51	02/29/2012	Electronic
Class A	03/02/2012	RSUs/Options Exercise	AcelRx Pharmaceuticals	<input type="checkbox"/>	845	02/29/2012	Electronic
Class A	08/31/2012	RSUs/Options Exercise	AcelRx Pharmaceuticals	<input type="checkbox"/>	117	03/02/2012	Electronic
Class A	02/28/2013	RSUs/Options Exercise	AcelRx Pharmaceuticals	<input type="checkbox"/>	71	08/31/2012	Electronic
Class A	03/02/2013	RSUs/Options Exercise	AcelRx Pharmaceuticals	<input type="checkbox"/>	845	03/02/2013	Electronic
Class A	03/02/2013	RSUs/Options Exercise	AcelRx Pharmaceuticals	<input type="checkbox"/>	845	03/02/2013	Electronic
Class A	08/30/2013	RSUs/Options Exercise	AcelRx Pharmaceuticals	<input type="checkbox"/>	72	08/30/2013	Electronic
Class A	02/28/2014	RSUs/Options Exercise	AcelRx Pharmaceuticals	<input type="checkbox"/>	121	02/28/2014	Electronic
Class A	08/29/2014	RSUs/Options Exercise	AcelRx Pharmaceuticals	<input type="checkbox"/>	124	08/29/2014	Electronic
Class A	02/27/2015	RSUs/Options Exercise	AcelRx Pharmaceuticals	<input type="checkbox"/>	125	02/27/2015	Electronic
Class A	03/12/2015	RSUs/Options Exercise	AcelRx Pharmaceuticals	<input type="checkbox"/>	1250	03/12/2015	Electronic
Class A	08/21/2015	RSUs/Options Exercise	AcelRx Pharmaceuticals	<input type="checkbox"/>	1450	08/21/2015	Electronic

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks Mrs. Palmer is an officer of AcelRx Pharmaceuticals and trustee of the Pamela P Palmer Revocable Trust DTD 10/17/2014

Date of Notice 08/25/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading

instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ UBS Financial Services Inc, as attorney-in-fact for Pamela Palmer, Trustee of the Pamela P Palmer Revocable Trust DTD 10/17/2014

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)